VieCure, N-Power Partner to Expand Trials in Community Oncology
Bringing AI-enabled medical determination assist and real-time potential medical information to develop analysis alternatives and enhance affected person outcomes
N-Power Medicine, an organization revolutionizing oncology drug growth, and VieCure, a frontrunner in AI-powered oncology intelligence, in the present day introduced a strategic partnership to carry N-Power Medicine’s proprietary Kaleido Registry
to the VieCure community. Through this collaboration, VieCure’s group oncology practices will achieve entry to each VieCure’s Halo Intelligence Platform and N-Power’s next-generation infrastructure, together with its always-on Prospective External Control Arm (ProECA) platform. This mannequin permits extra group oncology practices to incorporate cutting-edge analysis into affected person therapy plans whereas delivering precision drugs insights immediately on the level of care.
The collaboration addresses a vital hole in most cancers drug growth, the place fewer than 5% of grownup most cancers sufferers take part in medical trials – typically due to restricted entry in group settings the place 85% of sufferers obtain care. VieCure’s superior AI-enabled oncology intelligence platform and N-Power’s potential, consented, medical information mannequin create a strong ecosystem that accelerates precision drugs supply and broadens entry to medical trials in the group.
“This partnership represents a elementary shift in how we strategy medical trial entry and precision drugs in group oncology,” mentioned Michael Power, CEO of VieCure. “With N-Power’s real-time potential information strategy and the Halo Intelligence platform, we’re not simply bettering trial matching, we’re making a seamless workflow that transforms each affected person encounter into a chance for precision drugs and medical analysis participation. This is the way forward for increasing entry in community-based most cancers care.”
N-Power’s Kaleido Registry is a first-of-its-kind, AI-enabled, human-in-the-loop information engine that prospectively captures medical trial-grade information on the level of care, earlier than therapy selections are made. Through this partnership, group oncologists in the VieCure community can entry real-time medical trial alternatives and precision drugs insights immediately inside current workflows, offering oncologists with fast suggestions for each therapy optimization and medical trial eligibility in the intervening time of care decision-making.
“Strengthening the tradition of analysis in group oncology requires folks, methods to enhance medical effectivity, and expertise,” mentioned Michael Seiden, MD, PhD, Chief Medical Officer of N-Power Medicine. “The complementarity between VieCure’s Halo Intelligence platform and N-Power’s human-in-the-loop Kaleido Registry infrastructure creates a perfect alternative to unlock the potential of group oncology to play a serious position in accelerating drug growth and increasing sufferers’ entry to novel therapies.”
This collaboration leverages the complementary experience, expertise, and know-how of VieCure and N-Power Medicine to advance the standing of group oncology as a frontrunner in the evolution of customized most cancers care and accelerated therapeutic developments in oncology.
The put up VieCure, N-Power Partner to Expand Trials in Community Oncology first appeared on AI-Tech Park.
